Not sure if GLP-1 therapy is right for you?
Take the free 5-minute Indian-guideline check to see if you may be a candidate — Indian BMI thresholds, instant result.
Check My Eligibility →What this means for Indian patients
This source is India-specific. It directly reflects the clinical landscape, patient demographics, and guideline context that apply to Indian patients considering GLP-1 therapy. The findings are part of the evidence base GLP-1 Check uses for Indian-guideline-based eligibility assessment — meaning if you are an Indian patient, the conclusions here apply to you with minimal extrapolation.
Apply this evidence
GLP-1 therapy by condition →
PCOS, T2D, NAFLD, hypertension, sleep apnea — Indian guideline framing
India semaglutide brands →
All 12 DCGI-approved brands, prices from ₹220
GLP-1 brand comparisons →
Ozempic vs Wegovy, Mounjaro vs Wegovy, and more
Free Indian-guideline eligibility check →
5 minutes · Indian BMI thresholds · instant result
Related Sources
GLP-1 Receptor Agonists: Cardiovascular, Mortality, and Kidney Outcomes — Systematic Review and Meta-Analysis (Lancet 2021)
Clinical TrialSELECT Trial — Semaglutide 2.4 mg Cuts CV Events 20% (NEJM 2023)
Clinical TrialSTEP UP Trial: Semaglutide 7.2mg Achieves 20.7% Mean Weight Loss Over 72 Weeks
2026
Check if this evidence applies to you
Take the free 5-minute triage to get your GLP-1 Readiness Score.
Check My Eligibility →